

# E Dianne Pulte

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8728681/publications.pdf>

Version: 2024-02-01

66  
papers

3,319  
citations

218662

26  
h-index

144002

57  
g-index

66  
all docs

66  
docs citations

66  
times ranked

5276  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st Century: A Period Analysis. <i>Oncologist</i> , 2010, 15, 994-1001.  | 3.7 | 623       |
| 2  | Recent major improvement in long-term survival of younger patients with multiple myeloma. <i>Blood</i> , 2008, 111, 2521-2526.  | 1.4 | 495       |
| 3  | Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. <i>Blood</i> , 2009, 113, 1408-1411.  | 1.4 | 202       |
| 4  | Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. <i>Blood</i> , 2008, 111, 4916-4921.   | 1.4 | 133       |
| 5  | Improvement in Survival of Older Adults with Multiple Myeloma: Results of an Updated Period Analysis of SEER Data. <i>Oncologist</i> , 2011, 16, 1600-1603.   | 3.7 | 131       |
| 6  | Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. <i>Haematologica</i> , 2009, 94, 270-275.   | 3.5 | 113       |
| 7  | Trends in 5- and 10-year Survival After Diagnosis with Childhood Hematologic Malignancies in the United States, 1990-2004. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1301-1309.                            | 6.3 | 107       |
| 8  | Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. <i>Blood</i> , 2008, 111, 2977-2983.  | 1.4 | 103       |
| 9  | Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. <i>Haematologica</i> , 2008, 93, 594-600.  | 3.5 | 99        |
| 10 | Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups. <i>Haematologica</i> , 2013, 98, 222-229. | 3.5 | 86        |
| 11 | Survival of Adults with Acute Lymphoblastic Leukemia in Germany and the United States. <i>PLoS ONE</i> , 2014, 9, e85554.   | 2.5 | 86        |
| 12 | Recent improvement in survival of patients with multiple myeloma: variation by ethnicity. <i>Leukemia and Lymphoma</i> , 2014, 55, 1083-1089.   | 1.3 | 82        |
| 13 | Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century. <i>British Journal of Haematology</i> , 2015, 171, 189-196.   | 2.5 | 80        |
| 14 | Ongoing Improvement in Outcomes for Patients Diagnosed as Having Non-Hodgkin Lymphoma From the 1990s to the Early 21st Century. <i>Archives of Internal Medicine</i> , 2008, 168, 469.  | 3.8 | 78        |
| 15 | Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. <i>Blood Cancer Journal</i> , 2020, 10, 56.   | 6.2 | 67        |
| 16 | CD39 Expression on T Lymphocytes Correlates With Severity of Disease in Patients With Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 367-372.                                       | 0.4 | 63        |
| 17 | Trends in survival after diagnosis with hematologic malignancy in adolescence or young adulthood in the United States, 1981-2005. <i>Cancer</i> , 2009, 115, 4973-4979.   | 4.1 | 56        |
| 18 | Changes in the survival of older patients with hematologic malignancies in the early 21st century. <i>Cancer</i> , 2016, 122, 2031-2040.  | 4.1 | 46        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation. <i>Clinical Cancer Research</i> , 2021, 27, 3515-3521.  | 7.0  | 42        |
| 20 | Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century. <i>Journal of Hematology and Oncology</i> , 2016, 9, 28.                     | 17.0 | 40        |
| 21 | FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia. <i>Oncologist</i> , 2018, 23, 1366-1371.   | 3.7  | 40        |
| 22 | Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level. <i>Haematologica</i> , 2008, 93, 1544-1549.              | 3.5  | 39        |
| 23 | Subsite-specific colorectal cancer risk in the colorectal endoscopy era. <i>Gastrointestinal Endoscopy</i> , 2012, 75, 621-630.e1.   | 1.0  | 39        |
| 24 | Survival of Patients with Chronic Myelocytic Leukemia: Comparisons of Estimates from Clinical Trial Settings and Population-Based Cancer Registries. <i>Oncologist</i> , 2011, 16, 663-671.                      | 3.7  | 34        |
| 25 | Disparities in Colon Cancer Survival by Insurance Type: A Population-Based Analysis. <i>Diseases of the Colon and Rectum</i> , 2018, 61, 538-546.  | 1.3  | 33        |
| 26 | Survival for patients with chronic leukemias in the US and Britain: Age-related disparities and changes in the early 21st century. <i>European Journal of Haematology</i> , 2015, 94, 540-545.                   | 2.2  | 29        |
| 27 | Social disparities in survival after diagnosis with colorectal cancer: Contribution of race and insurance status. <i>Cancer Epidemiology</i> , 2017, 48, 41-47.  | 1.9  | 25        |
| 28 | Nonsurgical therapies for resected and unresected pancreatic cancer in Europe and USA in 2003–2014: a large international population-based study. <i>International Journal of Cancer</i> , 2018, 143, 3227-3239. | 5.1  | 25        |
| 29 | Survival Disparities by Insurance Type for Patients Aged 15–64 Years With Non-Hodgkin Lymphoma. <i>Oncologist</i> , 2015, 20, 554-561.   | 3.7  | 21        |
| 30 | Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century. <i>Journal of Hematology and Oncology</i> , 2013, 6, 70.                         | 17.0 | 20        |
| 31 | Survival of patients with non-Hodgkin lymphoma in Germany in the early 21st century. <i>Leukemia and Lymphoma</i> , 2013, 54, 979-985.   | 1.3  | 20        |
| 32 | Survival Expectations of Patients Diagnosed with Hodgkin's Lymphoma in 2006–2010. <i>Oncologist</i> , 2009, 14, 806-813.   | 3.7  | 19        |
| 33 | Expected long-term survival of older patients diagnosed with non-Hodgkin lymphoma in 2008–2012. <i>Cancer Epidemiology</i> , 2012, 36, e19-e25.  | 1.9  | 19        |
| 34 | Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications. <i>Blood Advances</i> , 2018, 2, 116-119.  | 5.2  | 19        |
| 35 | Age disparities in survival from lymphoma and myeloma: a comparison between US and England. <i>British Journal of Haematology</i> , 2014, 165, 824-831.  | 2.5  | 18        |
| 36 | Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21st century. <i>British Journal of Haematology</i> , 2014, 164, 851-857.  | 2.5  | 17        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Survival in patients with acute myeloblastic leukemia in Germany and the United States: Major differences in survival in young adults. <i>International Journal of Cancer</i> , 2016, 139, 1289-1296.                                | 5.1 | 17        |
| 38 | Long-term survival of patients diagnosed with non-Hodgkin lymphoma after a previous malignancy. <i>Leukemia and Lymphoma</i> , 2009, 50, 179-186.  | 1.3 | 16        |
| 39 | Case series of octogenarians with sickle cell disease. <i>Blood</i> , 2016, 128, 2367-2369.  | 1.4 | 16        |
| 40 | Changes in population-level survival for advanced solid malignancies with new treatment options in the second decade of the 21st century. <i>Cancer</i> , 2019, 125, 2656-2665.  | 4.1 | 15        |
| 41 | Survival of patients with gastric lymphoma in Germany and in the United States. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1485-1491.   | 2.8 | 13        |
| 42 | Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses. <i>Journal of Clinical Oncology</i> , 2022, 40, 847-854. | 1.6 | 13        |
| 43 | Survival disparities by age and country of diagnosis for patients with acute leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2787-2792.   | 1.3 | 10        |
| 44 | Outcome disparities by insurance type for patients with acute myeloblastic leukemia. <i>Leukemia Research</i> , 2017, 56, 75-81.   | 0.8 | 9         |
| 45 | Comparison of Emergency Department Wait Times in Adults with Sickle Cell Disease Versus Other Painful Etiologies. <i>Hemoglobin</i> , 2016, 40, 330-334.   | 0.8 | 8         |
| 46 | Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21st century. <i>Haematologica</i> , 2017, 102, e229-e232.                                   | 3.5 | 8         |
| 47 | Survival for patients with rare haematologic malignancies: Changes in the early 21st century. <i>European Journal of Cancer</i> , 2017, 84, 81-87.   | 2.8 | 8         |
| 48 | Population-Level Differences in Rectal Cancer Survival in Uninsured Patients Are Partially Explained by Differences in Treatment. <i>Oncologist</i> , 2017, 22, 351-358.   | 3.7 | 7         |
| 49 | Erythropoietin Levels in Patients with Sickle Cell Disease Do Not Correlate with Known Inducers of Erythropoietin. <i>Hemoglobin</i> , 2014, 38, 385-389.  | 0.8 | 6         |
| 50 | Red Cell Alloimmunization in Sickle Cell Disease: Benefit of Extended Crossmatching in Adults. <i>Blood</i> , 2012, 120, 4761-4761.  | 1.4 | 6         |
| 51 | Survival of patients with hepatobiliary tract and duodenal cancer sites in Germany and the United States in the early 21st century. <i>International Journal of Cancer</i> , 2018, 143, 324-332.                                     | 5.1 | 5         |
| 52 | Long-term survival in chronic myelocytic leukemia after a first primary malignancy. <i>Leukemia Research</i> , 2009, 33, 1604-1608.  | 0.8 | 4         |
| 53 | Population-Level Survival for Patients With Chronic Myeloid Leukemia: Higher Survival in Sweden Than Internationally. <i>Journal of Clinical Oncology</i> , 2017, 35, 695-696.   | 1.6 | 2         |
| 54 | Erythropoietin Levels in Patients with Sickle Cell Disease Not in Vaso-Occlusive Crisis. <i>Blood</i> , 2012, 120, 3242-3242.  | 1.4 | 2         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Incidence and survival estimates for patients with myelodysplastic syndrome in the early 21st century: no evidence of improvement over time. <i>Leukemia and Lymphoma</i> , 2022, 63, 1964-1969.   | 1.3 | 2         |
| 56 | Determining the role of smoking in myeloproliferative neoplasms: is it a matter of picking the right control group?. <i>European Journal of Haematology</i> , 2016, 97, 3-4.   | 2.2 | 1         |
| 57 | U.S. Food and Drug Administration Benefitâ€Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission. <i>Oncologist</i> , 2019, 24, e188-e195.       | 3.7 | 1         |
| 58 | Influence of insurance type on survival in patients with acute myeloblastic leukemia.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17612-e17612.  | 1.6 | 1         |
| 59 | In Reply. <i>Oncologist</i> , 2015, 20, 1224-1224.   | 3.7 | 0         |
| 60 | Ongoing Strong Improvement in Treatment Outcomes for Patients Diagnosed with Non-Hodgkin Lymphoma from the 1990s to the Early 21st Century.. <i>Blood</i> , 2007, 110, 3314-3314.  | 1.4 | 0         |
| 61 | Population Level Survival for Patients with Multiple Myeloma: Variation and Growing Disparity for Patients of Minority Race or Ethnicity. <i>Blood</i> , 2011, 118, 3126-3126.   | 1.4 | 0         |
| 62 | Changes in Survival in Acute Myeloblastic Leukemia by Racial and Ethnic Group: Greater Improvement for Non-Hispanic Whites and Increase in the Disparity for Minority Patients in the Early 21st Century. <i>Blood</i> , 2011, 118, 844-844. | 1.4 | 0         |
| 63 | Population Level Survival of Patients with Chronic Myeloid Leukemia in Germany in the Early 21st Century. <i>Blood</i> , 2012, 120, 759-759.   | 1.4 | 0         |
| 64 | An International Comparison Of Survival Disparities In Patients With Lymphoma and Myeloma. <i>Blood</i> , 2013, 122, 2925-2925.  | 1.4 | 0         |
| 65 | Survival Disparities By Insurance Type For Patients With Non-Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 1737-1737.  | 1.4 | 0         |
| 66 | Characteristics of "Older Old" Patients with Sickle Cell Anemia Who Survived for More Than 80 Years. <i>Blood</i> , 2015, 126, 4599-4599.  | 1.4 | 0         |